Vienna, Austria, 14 June 2021:
CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the launch of Danube Labs, a partnership with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) to fast-track early-stage academic research to drug discovery and development. The joint project, financed by a dedicated group of private investors, will identify, and develop academic projects into mature therapeutic product development opportunities, primed for biotech company formation or partnering. Danube Labs aims to create up to 8 new biotech companies over 4 years, and is supported by CEBINA Bridge Capital Limited, a private fund established in Gibraltar and committed to providing a minimum investment of € 10 m.
'We are excited to join forces with Evotec to expand our mission to transform promising research and early-stage drug discovery projects from Central and Eastern Europe into mature projects attractive for forming new companies that will be embedded in the biotech ecosystem CEBINA has created. This partnership brings together great entrepreneurial expertise and experience in drug development that, we believe, will enable us to generate breakthrough therapeutics,' commented Eszter Nagy, MD PhD, founder and CEO&CSO of CEBINA.
'Danube Labs represents the latest of Evotec's BRIDGE partnerships, where we explore exciting academic science with the aim to accelerate the translation of early-stage drug discovery from academia to patients,' commented Mark Slack, PhD, VP Academic Partnerships at Evotec. 'Through our partnership with CEBINA, we see the opportunity to seek out and validate promising innovative research in Central and Eastern Europe'.
For further information on Danube Labs, please follow this link to the full version of CEBINA's press release.
Evotec SE published this content on 14 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2021 08:10:04 UTC.